TRP's 4QFY21 result was marginally below our estimates at an operational level, led by a sharp YoY decline in US and CRAMS sales. It continues to build its product portfolio and enhance marketing efforts to outperform in Brazil, Germany, and the Branded Generics segment in Domestic Formulation (DF)....